Results 61 to 70 of about 18,162 (243)

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy

Infection and Drug Resistance, 2010
Charlotte Charpentier1, Laurence Weiss21Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université Paris-Diderot, Paris, France; 2Assistance Publique-Hôpitaux de ...
Charlotte Charpentier, Laurence Weiss
doaj  

Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration [PDF]

, 2017
Objectives The site of pharmacological activity of raltegravir is intracellular. Our aim was to determine the extent of raltegravir cellular penetration and whether raltegravir total plasma concentration (Ctot) predicts cellular concentration (Ccell ...
Biollaz, Jérôme, Buclin, Thierry, Cavassini, Matthias, Colombo, Sara, Cruchon, Sandra, Decosterd, Laurent A., Fayet Mello, Aurélie, Franc, Claudia, Guignard, Nicole, Telenti, Amalio   +9 more
core  

Longitudinal sequencing of HIV-1 infected patients with low-level viremia for years while on ART shows no indications for genetic evolution of the virus [PDF]

, 2017
HIV-infected patients on antiretroviral therapy (ART) may present low-level viremia (LLV) above the detection level of current viral load assays.
Dauwe, Kenny, Demecheleer, Els, Dinakis, Sylvie, Hebberecht, Laura, Mortier, Virginie, Vancoillie, Leen, Vaneechoutte, Dries, Verhofstede, Chris   +7 more
core   +1 more source

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, Volume 27, Issue 5, Page 749-760, May 2026.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source

Novel Perspectives on the Design and Development of a Long-Acting Subcutaneous Raltegravir Injection for Treatment of HIV—In Vitro and In Vivo Evaluation

Pharmaceutics, 2023
Antiretrovirals (ARVs) are a highly effective therapy for treatment and prevention of HIV infection, when administered as prescribed. However, adherence to lifelong ARV regimens poses a considerable challenge and places HIV patients at risk.
Heba S. Abd-Ellah, Ramesh Mudududdla, Glen P. Carter, Jonathan B. Baell   +3 more
doaj   +1 more source

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis [PDF]

, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Chiara Tommasi, Rita Bellagamba, Massimo Tempestilli, Antonio D'Avolio, Anna L Gallo, Jelena Ivanovic, Emanuele Nicastri, Leopoldo P Pucillo, Pasquale Narciso   +8 more
core   +2 more sources

Perinatal and early infant outcomes after first‐versus second‐generation integrase strand transfer inhibitor use in pregnancy

HIV Medicine, Volume 27, Issue 5, Page 761-770, May 2026.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Rosa Balleny, Jeffrey Man Hay Wong, Terry Lee, Ari Bitnun, Isabelle Boucoiran, Jason Brophy, Jeannette Comeau, Fatima Kakkar, Athena McConnell, Laura Sauvé, Joel Singer, Alena Tse‐Chang, Deborah Money   +12 more
wiley   +1 more source

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

European Journal of Medical Research, 2009
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj   +1 more source

Quantitative PCR used to Assess HIV-1 Integration and 2-LTR Circle Formation in Human Macrophages, Peripheral Blood Lymphocytes and a CD4+ Cell Line [PDF]

, 2010
Background Integration is an intermediate step in the HIV life cycle and is defined as the insertion of HIV-1 proviral DNA into the host chromosome. If integration does not occur when HIV-1 cDNA enters the nucleus, it circularizes upon itself
Brian Friedrich, Guangyu Li, Natallia Dziuba, Monique R Ferguson   +3 more
core   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source